{"filing":{"accession_number":"0001833141-26-000048","cik":"0001833141","ticker":"HELP","company_name":"CYBIN INC.","form":"6-K","filing_date":"2026-06-29","report_date":null,"primary_document":"cybininc-form6xk06x29x2026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1833141/000183314126000048/cybininc-form6xk06x29x2026.htm"},"events":[{"id":14737,"run_id":13129,"accession_number":"0001833141-26-000048","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This exhibit is a press release announcing audited financial results for Helus Pharma's fiscal year ended March 31, 2026, including net loss of $148.0 million, cash position of $157.3 million, and operating cash flows of $133.3 million. The document explicitly states \"Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results\" and discloses quarterly and annual financial metrics alongside clinical pipeline updates. This is a discrete earnings announcement, not a periodic financial report itself, and is material to investors assessing the company's financial position and burn rate.","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-06-29","form":"6-K","submitted_at":null,"items":[{"id":12259,"accession_number":"0001833141-26-000048","item_number":"EX-99.1","item_title":"finalfiscalyear2026financi.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing audited financial results for Helus Pharma's fiscal year ended March 31, 2026, including net loss of $148.0 million, cash position of $157.3 million, and operating cash flows of $133.3 million. The document explicitly states \"Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results\" and discloses quarterly and annual financial metrics alongside clinical pipeline updates. This is a discrete earnings announcement, not a periodic financial report itself, and is material to investors assessing the company's financial position and burn rate.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T21:11:38.375659+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12259,"accession_number":"0001833141-26-000048","item_number":"EX-99.1","item_title":"finalfiscalyear2026financi.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing audited financial results for Helus Pharma's fiscal year ended March 31, 2026, including net loss of $148.0 million, cash position of $157.3 million, and operating cash flows of $133.3 million. The document explicitly states \"Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results\" and discloses quarterly and annual financial metrics alongside clinical pipeline updates. This is a discrete earnings announcement, not a periodic financial report itself, and is material to investors assessing the company's financial position and burn rate.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T21:11:38.375659+00:00","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-06-29"}]}